Phase 2/3Not yet recruiting
Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized Trial (TOPAZ)
Effect of Tirzepatide on Functional Outcomes in Patients With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy: A Multicenter, Randomized, Controlled, Blinded Outcome Assessment Trial
- Sponsor
- yifang zhu (Academic or other)
- Enrolment
- 726 planned
- Conditions
- Acute Ischemic Stroke (AIS)
- Interventions
- Tirzepatide; Standard Medical Care (SMC)
- Ages
- adults, older adults
- Registry
- NCT07734792
From the registry
Acute ischemic stroke caused by blockage of a large artery in the brain is one of the leading causes of death and long-term disability worldwide. For patients with this type of stroke, endovascular thrombectomy (EVT), a procedure that removes the blood clot and restores blood flow to the brain, has become the standard treatment. However, even when blood flow is successfully restored, many patients continue to experience disability because of ongoing brain injury caused by inflammation, oxidative stress, and damage to brain cells after the stroke. This study aims to evaluate whether tirzepatide, a medication that activates both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) pathways, can improve recovery in patients with acute ischemic stroke caused by large vessel occlusion who receive thrombectomy. Tirzepatide is currently approved for the treatment of conditions such as type 2 diabetes and obesity. Previous studies have shown that tirzepatide can improve blood sugar control, reduce body weight, and provide beneficial effects on…
Primary outcomes
- The primary efficacy outcome: Proportion of patients achieving an excellent functional outcome
- The primary safety outcome: All-cause mortality